Identification of Carnitine-Responsive Cardiomyopathy (C001)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2013 by University Health Network, Toronto
Sponsor:
Collaborator:
The Physicians' Services Incorporated Foundation
Information provided by (Responsible Party):
Hanna Faghfoury, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01904396
First received: July 15, 2013
Last updated: July 17, 2013
Last verified: July 2013

July 15, 2013
July 17, 2013
August 2013
August 2016   (final data collection date for primary outcome measure)
Serum Carnitine Concentration [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Measurement of free and total serum carnitine concentrations will be performed using isotope-dilution mass spectrometry.
Same as current
Complete list of historical versions of study NCT01904396 on ClinicalTrials.gov Archive Site
  • Echocardiographic Measures [ Time Frame: Baseline, every 6m for up to 2 years ] [ Designated as safety issue: No ]

    Measurements include:

    Septal diameter Left Ventricular (LV) mass LV ejection fraction LV end-systolic volume LV end-diastolic measure

  • B-Natriuretic Peptide (BNP) [ Time Frame: Baseline, every 6m for up to 2 years ] [ Designated as safety issue: No ]
    An elevated BNP level is a marker of increased LV filling pressures and LV dysfunction and is highly correlated with severity of, and prognosis in, heart failure. BNP testing is routinely performed at the cardiac clinic at University Health Network to determine treatment response and to assist with risk stratification prognostication in patients with heart failure.
Same as current
Not Provided
Not Provided
 
Identification of Carnitine-Responsive Cardiomyopathy
Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness.

There are some adults with skeletal muscle weakness (called "myopathy") and heart muscle weakness (called "cardiomyopathy") who have low blood levels of a compound called carnitine as a cause of their problems. Carnitine is very important to energy production in muscles. In fact, there are reports of some people with carnitine deficiency who have developed myopathy and cardiomyopathy that was completely reversed with carnitine treatment. The main objective of our project is to determine the number of patients who have carnitine deficiency as a cause of their myopathy and cardiomyopathy. The investigators will be measuring carnitine levels in 1000 patients with cardiomyopathy and will describe the specific features in all the study patients to see if there are any trends that may help us predict which patients with muscle weakness are at risk of developing low carnitine levels. The investigators will be treating patients with low carnitine levels with carnitine and observing them to see if their cardiomyopathy and their muscle weakness improve. Knowing the exact percentage of myopathy and cardiomyopathy patients with carnitine deficiency may allow for screening of patients in a cheap and targeted way to treat the serious complication of this condition, including heart failure and sudden death.

The primary objective of this research is to determine the prevalence of primary and secondary (genetic and acquired) carnitine deficiency in patients with limb girdle weakness and hypertrophic or idiopathic dilated cardiomyopathy where an underlying cause is unknown. Identification and treatment with carnitine may potentially reverse or halt heart failure and skeletal muscle weakness in these patients.

Specific aims:

  1. To ascertain the prevalence of primary and secondary carnitine deficiency in a population of adults with myopathy and hypertrophic and dilated cardiomyopathy of unknown etiology
  2. To describe the demographic and phenotypic characteristics of patients with myopathy and dilated or hypertrophic cardiomyopathy who have primary and secondary carnitine deficiency
  3. To measure the motor and cardiovascular response to carnitine supplementation in patients with myopathy, cardiomyopathy and carnitine deficiency
Interventional
Phase 4
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Carnitine Deficiency
Drug: Carnitine
Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
Other Name: Carnitor
Experimental: CarnitineDeficient
Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
Intervention: Drug: Carnitine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
30
December 2016
August 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • An adult patient (>18 years) with a diagnosis of either hypertrophic or dilated cardiomyopathy, for which the underlying etiology of the cardiomyopathy is unknown.

Exclusion Criteria:

  • A history of ischemia
  • A documented or suspected infection including HIV
  • A history of severe longstanding hypertension
  • A history of valvular heart disease
  • A history of chemotherapy exposure
  • A history of alcohol abuse
  • Carnitine supplementation at the time of recruitment
Both
18 Years and older
No
Contact: Hanna Faghfoury hanna.faghfoury@uhn.ca
Canada
 
NCT01904396
Carnitine001
No
Hanna Faghfoury, University Health Network, Toronto
University Health Network, Toronto
The Physicians' Services Incorporated Foundation
Principal Investigator: Faghfoury Hannaneh, MD University Health Network, Toronto, Ontario
Principal Investigator: Ingrid Tein, MD The Hospital for Sick Children, Toronto, Ontario
University Health Network, Toronto
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP